Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).
Article
Omuro, Antonio Marcilio Padula, DeAngelis, Lisa Marie, Karrison, Theodore et al. (2020). Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).
. JOURNAL OF CLINICAL ONCOLOGY, 38(15_suppl), 2501-2501. 10.1200/jco.2020.38.15_suppl.2501
Omuro, Antonio Marcilio Padula, DeAngelis, Lisa Marie, Karrison, Theodore et al. (2020). Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).
. JOURNAL OF CLINICAL ONCOLOGY, 38(15_suppl), 2501-2501. 10.1200/jco.2020.38.15_suppl.2501